Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 11 (November)

1. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
   Exp Hematol, 35(11): 1723-7. [Abstract] [Full-text]
2. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.
   Lancet Oncol, 8(11): 1018-29. [Abstract] [Full-text]
3. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
   Blood, 110(10): 3540-6. [Abstract] [Full-text]
4. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
   Blood, 110(10): 3552-6. [Abstract] [Full-text]
5. Advanced pediatric inoperable thymus carcinoma (type C thymoma): case report on a novel therapeutic approach.
   J Pediatr Hematol Oncol, 29(11): 774-5. [Abstract] [Full-text]
6. Nilotinib therapy in chronic myelogenous leukemia.
   Drugs Today (Barc), 43(10): 691-702. [Abstract] [Full-text]
7. Successful Imatinib Treatment of Cardiac Involvement of FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia Followed by Severe Hepatotoxicity.
   Int J Hematol, 86(3): 233-7. [Abstract] [Full-text]
8. Cytogenetic Remissions Induced by Interferon alpha and Imatinib Mesylate are Immunologically Distinct in Chronic Myeloid Leukemia.
   Int J Hematol, 86(3): 208-11. [Abstract] [Full-text]
9. Pancreatic cancer and the FAMMM syndrome.
   Fam Cancer. [Abstract] [Full-text]
10. Management of imatinib-resistant CML patients.
    Onkologie, 30(11): 574-80. [Abstract] [Full-text]
11. Gastric and prostate adenocarcinoma in a patient with metastatic gastrointestinal stromal tumor.
    Onkologie, 30(11): 568-70. [Abstract] [Full-text]
12. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571).
    Ann Oncol, 18(11): 1834-41. [Abstract] [Full-text]
13. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.
    Cancer Cell, 12(5): 467-78. [Abstract] [Full-text]
14. Pentavalent technetium-99m dimercaptosuccinic acid [99m Tc-(V)DMSA] brain scintitomography--a plausible non-invasive depicter of glioblastoma proliferation and therapy response.
    J Neurooncol, 85(3): 291-5. [Abstract] [Full-text]
15. Imatinib inhibition of fludarabine uptake in T-lymphocytes.
    Cancer Chemother Pharmacol. [Abstract] [Full-text]
16. Role of hemoclips in the management of acute bleeding from a gastric stromal tumor: a case report and review of the literature.
    J Med Case Reports, 1(1): 136. [Abstract] [Full-text]
17. Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells.
    Toxicol In Vitro, 21(8): 1678-85. [Abstract] [Full-text]
18. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Clin Cancer Res, 13(22): 6727-34. [Abstract] [Full-text]
19. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.
    Medicine (Baltimore), 86(6): 344-54. [Abstract] [Full-text]
20. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
    Differentiation, 75(9): 843-52. [Abstract] [Full-text]
21. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder.
    Leuk Res, 32(1): 169-71. [Abstract] [Full-text]
22. Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.
    Mol Pharmacol, 72(6): 1440-6. [Abstract] [Full-text]
23. Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib.
    Leuk Res, 32(1): 177-80. [Abstract] [Full-text]
24. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
    Blood, 110(12): 4005-11. [Abstract] [Full-text]
25. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.
    Blood, 110(12): 4064-72. [Abstract] [Full-text]
26. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
    Blood, 110(12): 4055-63. [Abstract] [Full-text]
27. Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase.
    Haematologica, 92(11): 1579-80. [Abstract] [Full-text]
28. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Haematologica, 92(11): 1451-9. [Abstract] [Full-text]
29. Management of Bcr-Abl-positive leukemias with dasatinib.
    Expert Rev Anticancer Ther, 7(11): 1529-36. [Abstract] [Full-text]
30. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
    Leukemia, 21(12): 2420-7. [Abstract] [Full-text]
31. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
    Leukemia, 21(12): 2485-94. [Abstract] [Full-text]
32. Rapid detection of BCR-ABL fusion genes using a novel combined LUX primer, in-cell RT-PCR and flow cytometric method.
    Ann Hematol, 87(1): 35-41. [Abstract] [Full-text]
33. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
    AJR Am J Roentgenol, 189(6): W324-30. [Abstract] [Full-text]
34. Successful Resection of an Advanced Duodenal Gastrointestinal Stromal Tumor After Down-Staging with Imatinib: Report of a Case.
    Surg Today, 37(12): 1105-1109. [Abstract] [Full-text]
35. Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia.
    Acta Haematol, 118(4): 205-208. [Abstract] [Full-text]
36. Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease.
    Cancer J, 13(6): 384-91. [Abstract] [Full-text]
37. New and old treatment modalities in primary myelofibrosis.
    Cancer J, 13(6): 377-83. [Abstract] [Full-text]
38. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
    Cancer J, 13(6): 357-65. [Abstract] [Full-text]
39. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Expert Opin Pharmacother, 8(18): 3257-64. [Abstract] [Full-text]
40. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.
    Int J Cancer, 122(2): 289-97. [Abstract] [Full-text]
41. KIT and PDGFRalpha mutational analyses of mixed cell-type gastrointestinal stromal tumours.
    Histopathology, 51(6): 758-62. [Abstract] [Full-text]
42. Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and leiomyosarcoma.
    Future Oncol, 3(6): 629-637. [Abstract] [Full-text]
43. State-of-the-art in the treatment of chronic myeloid leukaemia.
    Curr Opin Oncol, 20(1): 112-21. [Abstract] [Full-text]
44. Will targeted therapy hold its promise? An evidence-based review.
    Curr Opin Oncol, 20(1): 104-11. [Abstract] [Full-text]
45. A rare case of primary mesenteric gastrointestinal stromal tumor with metastasis to the cervix uteri.
    World J Surg Oncol, 5(1): 137. [Abstract] [Full-text]
46. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Oncogene, 26(54): 7560-8. [Abstract] [Full-text]
47. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring.
    Genome Biol, 8(11): R255. [Abstract] [Full-text]
48. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet.
    Clin Sci (Lond), 114(1): 65-71. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.